VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

MAGEA3

Gene Name MAGEA3
Sequence Strain (Species/Organism) Homo sapiens
NCBI Gene ID 4102
NCBI Protein GI 4885467
Genbank Accession AC244102
Protein Accession NP_005353
Taxonomy ID 9606
Chromosome No X
Gene Starting Position 152698741
Gene Ending Position 152702346
Gene Strand (Orientation) +
Protein Name transcript variant X2
Protein pI 4.25
Protein Weight 32564.28
Protein Length 314
DNA Sequence 
>NC_000023.11:152698741-152702346 Homo sapiens chromosome X, GRCh38.p12 Primary Assembly
CAGAAGACCGCGAGATTCTCGCCCTGAGCAACGAGCGACGGCCTGACGTCGGCGGAGGGAAGCCGGCCCA
GGCTCGGTGAGGAGGCAAGGTAAGACGCTGAGGGAGGACTGAGGCGGGCCTCACCTCAGACAGAGGGCCT
CAAATAATCCAGTGCTGCCTCTGCTGCCGGGCCTGGGCCACCCCGCAGGGGAAGACTTCCAGGCTGGGTC
GCCACTACCTCACCCCGCCGACCCCCGCCGCTTTAGCCACGGGGAACTCTGGGGACAGAGCTTAATGTGG
CCAGGGCAGGGCTGGTTAGAAGAGGTCAGGGCCCACGCTGTGGCAGGAATCAAGGTCAGGACCCCGAGAG
GGAACTGAGGGCAGCCTAACCACCACCCTCACCACCATTCCCGTCCCCCAACACCAACCCCACCCCCATC
CCCCATTCCCCATTCCCATCCCCACCCCCACCCCTATCCTGGCAGAATCCGGGCTTTGCCCCTGGTATCA
AGTCACGGAAGCTCCGGGAATGGCGGCCAGGCACGTGAGTCCTGAGGTTCACATCTACGGCTAAGGGAGG
GAAGGGGTTCGGTATCGCGAGTATGGCCGTTGGGAGGCAGCGAAAGGGCCCAGGCCCTCCTGGAAGACAG
TGGAGTCCTGAGGGGACCCAGCATGCCAGGACAGGGGGCCCACTGTACCCCTGTCTCAAACCGAGGCACC
TTTTCATTCGGCTACGGGAATCCTAGGGATGCAGACCCACTTCAGCAGGGGGTTGGGGCCCAGCCCTGCG
AGGAGTCATGGGGAGGAAGAAGAGGGAGGACTGAGGGGACCTTGGAGTCCAGATCAGTGGCAACCTTGGG
CTGGGGGATGCTGGGCACAGTGGCCAAATGTGCTCTGTGCTCATTGCGCCTTCAGGGTGACCAGAGAGTT
GAGGGCTGTGGTCTGAAGAGTGGGACTTCAGGTCAGCAGAGGGAGGAATCCCAGGATCTGCAGGGCCCAA
GGTGTACCCCCAAGGGGCCCCTATGTGGTGGACAGATGCAGTGGTCCTAGGATCTGCCAAGCATCCAGGT
GAAGAGACTGAGGGAGGATTGAGGGTACCCCTGGGACAGAATGCGGACTGGGGGCCCCATAAAAATCTGC
CCTGCTCCTGCTGTTACCTCAGAGAGCCTGGGCAGGGCTGTCAGCTGAGGTCCCTCCATTATCCTAGGAT
CACTGATGTCAGGGAAGGGGAAGCCTTGGTCTGAGGGGGCTGCACTCAGGGCAGTAGAGGGAGGCTCTCA
GACCCTACTAGGAGTGGAGGTGAGGACCAAGCAGTCTCCTCACCCAGGGTACATGGACTTCAATAAATTT
GGACATCTCTCGTTGTCCTTTCCGGGAGGACCTGGGAATGTATGGCCAGATGTGGGTCCCCTCATGTTTT
TCTGTACCATATCAGGTATGTGAGTTCTTGACATGAGAGATTCTCAGGCCAGCAGAAGGGAGGGATTAGG
CCCTATAAGGAGAAAGGTGAGGGCCCTGAGTGAGCACAGAGGGGATCCTCCACCCCAGTAGAGTGGGGAC
CTCACAGAGTCTGGCCAACCCTCCTGACAGTTCTGGGAATCCGTGGCTGCGTTTGCTGTCTGCACATTGG
GGGCCCGTGGATTCCTCTCCCAGGAATCAGGAGCTCCAGGAACAAGGCAGTGAGGACTTGGTCTGAGGCA
GTGTCCTCAGGTCACAGAGTAGAGGGGGCTCAGATAGTGCCAACGGTGAAGGTTTGCCTTGGATTCAAAC
CAAGGGCCCCACCTGCCCCAGAACACATGGACTCCAGAGCGCCTGGCCTCACCCTCAATACTTTCAGTCC
TGCAGCCTCAGCATGCGCTGGCCGGATGTACCCTGAGGTGCCCTCTCACTTCCTCCTTCAGGTTCTGAGG
GGACAGGCTGACCTGGAGGACCAGAGGCCCCCGGAGGAGCACTGAAGGAGAAGATCTGTAAGTAAGCCTT
TGTTAGAGCCTCCAAGGTTCCATTCAGTACTCAGCTGAGGTCTCTCACATGCTCCCTCTCTCCCCAGGCC
AGTGGGTCTCCATTGCCCAGCTCCTGCCCACACTCCCGCCTGTTGCCCTGACCAGAGTCATCATGCCTCT
TGAGCAGAGGAGTCAGCACTGCAAGCCTGAAGAAGGCCTTGAGGCCCGAGGAGAGGCCCTGGGCCTGGTG
GGTGCGCAGGCTCCTGCTACTGAGGAGCAGGAGGCTGCCTCCTCCTCTTCTACTCTAGTTGAAGTCACCC
TGGGGGAGGTGCCTGCTGCCGAGTCACCAGATCCTCCCCAGAGTCCTCAGGGAGCCTCCAGCCTCCCCAC
TACCATGAACTACCCTCTCTGGAGCCAATCCTATGAGGACTCCAGCAACCAAGAAGAGGAGGGGCCAAGC
ACCTTCCCTGACCTGGAGTCCGAGTTCCAAGCAGCACTCAGTAGGAAGGTGGCCGAGTTGGTTCATTTTC
TGCTCCTCAAGTATCGAGCCAGGGAGCCGGTCACAAAGGCAGAAATGCTGGGGAGTGTCGTCGGAAATTG
GCAGTATTTCTTTCCTGTGATCTTCAGCAAAGCTTCCAGTTCCTTGCAGCTGGTCTTTGGCATCGAGCTG
ATGGAAGTGGACCCCATCGGCCACTTGTACATCTTTGCCACCTGCCTGGGCCTCTCCTACGATGGCCTGC
TGGGTGACAATCAGATCATGCCCAAGGCAGGCCTCCTGATAATCGTCCTGGCCATAATCGCAAGAGAGGG
CGACTGTGCCCCTGAGGAGAAAATCTGGGAGGAGCTGAGTGTGTTAGAGGTGTTTGAGGGGAGGGAAGAC
AGTATCTTGGGGGATCCCAAGAAGCTGCTCACCCAACATTTCGTGCAGGAAAACTACCTGGAGTACCGGC
AGGTCCCCGGCAGTGATCCTGCATGTTATGAATTCCTGTGGGGTCCAAGGGCCCTCGTTGAAACCAGCTA
TGTGAAAGTCCTGCACCATATGGTAAAGATCAGTGGAGGACCTCACATTTCCTACCCACCCCTGCATGAG
TGGGTTTTGAGAGAGGGGGAAGAGTGAGTCTGAGCACGAGTTGCAGCCAGGGCCAGTGGGAGGGGGTCTG
GGCCAGTGCACCTTCCGGGGCCGCATCCCTTAGTTTCCACTGCCTCCTGTGACGTGAGGCCCATTCTTCA
CTCTTTGAAGCGAGCAGTCAGCATTCTTAGTAGTGGGTTTCTGTTCTGTTGGATGACTTTGAGATTATTC
TTTGTTTCCTGTTGGAGTTGTTCAAATGTTCCTTTTAACGGATGGTTGAATGAGCGTCAGCATCCAGGTT
TATGAATGACAGTAGTCACACATAGTGCTGTTTATATAGTTTAGGAGTAAGAGTCTTGTTTTTTACTCAA
ATTGGGAAATCCATTCCATTTTGTGAATTGTGACATAATAATAGCAGTGGTAAAAGTATTTGCTTAAAAT
TGTGAGCGAATTAGCAATAACATACATGAGATAACTCAAGAAATCAAAAGATAGTTGATTCTTGCCTTGT
ACCTCAATCTATTCTGTAAAATTAAACAAATATGCAAACCAGGATTTCCTTGACTTCTTTGAGAATGCAA
GCGAAATTAAATCTGAATAAATAATTCTTCCTCTTC
Protein Sequence 
>NP_005353.1 melanoma-associated antigen 3 [Homo sapiens]
MPLEQRSQHCKPEEGLEARGEALGLVGAQAPATEEQEAASSSSTLVEVTLGEVPAAESPDPPQSPQGASS
LPTTMNYPLWSQSYEDSSNQEEEGPSTFPDLESEFQAALSRKVAELVHFLLLKYRAREPVTKAEMLGSVV
GNWQYFFPVIFSKASSSLQLVFGIELMEVDPIGHLYIFATCLGLSYDGLLGDNQIMPKAGLLIIVLAIIA
REGDCAPEEKIWEELSVLEVFEGREDSILGDPKKLLTQHFVQENYLEYRQVPGSDPACYEFLWGPRALVE
TSYVKVLHHMVKISGGPHISYPPLHEWVLREGEE
Molecule Role Protective antigen
Molecule Role Annotation Vaccine- and tumor-specific immune responses of 10 melanoma patients treated with autologous GMLs expressing the cancer germline gene MAGE-A3 were analyzed. Three of 10 patients treated with MAGE-A3-GML showed an increase of circulating anti-MAGE-A3 T cells, and developed skin delayed-type hypersensitivity to MAGE-A3. Interestingly, in 2 of these patients, with progressive and measurable tumors at study entry, anti-MAGE-A3 T cells were detected not only in the blood but also within tumors resected after vaccination. These results demonstrate that the infusion of MAGE-A3-GML elicits antitumor T cells, which are capable of trafficking to inflamed tissues and of infiltrating tumors (Fontana et al., 2009).
Related Vaccines(s) 4-peptide melanoma vaccine , Allogeneic GM-CSF-Based Myeloma Cell Vaccine , Autologous Cancer Testis Antigen Specific Dendritic Cell Vaccine , Autologous CT7/MAGE-A3/WT1 mRNA-Electroporated Langerhans-Type Dendritic Cells , Autologous Dendritic Cell-Allogeneic Melanoma Tumor Cell Lysate Vaccine , Autologous TriMix-DC Melanoma Vaccine , Autologous-Cell Leukemia Vaccine , EP-2101 Vaccine , HLA-A1-Binding MAGE-1/MAGE-3 Multipeptide-Pulsed Autologous Dendritic Cell Vaccine , Immunotherapeutic GSK1572932A , MAGE-3.A1 Peptide Vaccine , MAGE-A1/MAGE-A3/NY-ESO-1 Peptides Vaccine , MAGE-A3 Peptide Vaccine , MAGE-A3-expressing Adenovirus Type 5 Vaccine , MAGE-A3/HPV 16 Peptide Vaccine , MART-1/gp100/Tyrosinase/MAGE-A3 Peptides-loaded Irradiated Allogeneic Plasmacytoid Dendritic Cells Vaccine , Melan-A/MAGE-3.DP4 Peptide Vaccine , MELITAC 12.1 Peptide Vaccine , Multi-epitope melanoma peptide vaccine , NA-17/MAGE-3.A2/NY-ESO-1 Peptide Vaccine , NA17.A2 Peptide Vaccine , NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine , NY-ESO-1/PRAME/MAGE-A3/WT-1 Peptide Vaccine
References